drugset / Trial / NCT01239394
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Phase 2
Completed
43 enrolled
Massachusetts General Hospital
Beth Israel Deaconess Medical Center · collabDana-Farber Cancer Institute · collabGlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment
Summary
Ofatumumab is a drug that works by attaching to the CD20 molecule found on the surface of cancerous B cells, and then triggering the death of those cells. It is approved by the FDA for treatment of another B-cell cancer, chronic lymphocytic leukemia, and also has evidence of success in people who's B-cell lymphomas have relapsed after initial treatments. In this research study we are looking to see if ofatumumab is effective and safe in treating previously untreated B-cell NHL.
Timeline
- Start
- 2010-12
- Primary completion
- 2013-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ofatumumab | Monoclonal antibody | — | Intravenous |